In Eiwit Neamd HAVCR1 Koe de Diagnose fan Seldsume Harsenstumoren Fersnelle. Mar Wa Sil It Echt Brûke?
May 21, 2026 · Frisian News
Researchers have identified HAVCR1 as a biomarker that could make testing for rare brain and eye cancers faster and less invasive. The finding raises questions about how quickly such discoveries move from lab to clinic, and whether rare disease patients will actually gain access.
FryskIn ûntdekking dy't dizze wike oankundige is, stelt dat hepatitis A-firusreseptor 1, of HAVCR1, foarkomt yn seldsume harsen- en rêchbonkemurchstumoren en eachkankers. De ûndersikers stelle dat it detektearjen fan dit eiwit mear ynfasive diagnostyske testen ferfange kin en dizze tumoren earder opfange kin. Dat klinkt op papier hoopfol. De wiere fraach is oft sikehûzen in nij testprotokol ynfiere sille foar sykten dy't jierliks miskien in pear tûzen minsken per kontinent treffe.
Seldsume kankers krije min ûndersyksfinansjerring, krekt om't se seldsum binne. Farmaseutyske bedriuwen mije se om't de merk lyts is. Sikehûssystemen ynvestearje net yn apparatuer en training foar oandwanings dy't se ien kear yn de pear jier sjogge. Sels as in bettere test bestiet, betsjutte traachheid en kosten faak dat pasjinten de âlde, minne test bliuwe krijen. In stúdzje yn in prestizjeus tydskrift feraret op harsels neat.
Nimmen hjir stelt dat HAVCR1-testen net helpe sille foar minsken dy't der tagong ta hawwe. It eiwit bestiet wier yn dizze tumoren, en bloedtesten binne goedkeaper en minder ynfasief as biopsyen. Mar it gat tusken in ûndersykspaper en in pasjint dy't de juste test flugger krijt, kin in desennia of langer duorje. Sikehûzen hawwe diagnostyske kitprodusinten nedich dy't betroubere HAVCR1-assays produsearje. Dy bedriuwen hawwe in grut genôch merk nedich. Fersekeringsstelsels moatte akkoard gean mei fergoeding fan de test. Dokters hawwe training nedich. Elke hinderpeal deadt momentum.
It ûndersyk seit ek net hoe krekt de test oare oandwanings útslút of hoefolle falske positiven it opsmyt. In biomarker dy't yn tumoren foarkomt, is allinnich nuttich as dizze net ek yn goedaardich weefsel foarkomt. It perskeberjocht mijt fragen oer spesifisiteit en gefoelichheid. Dy antwurden binne wichtiger as it ienfâldige feit dat it eiwit bestiet.
Seldsume syktegemienskippen fiere faak iere ûndersyksresultaten en wachtsje dan jierren op kommersjalisearring dy't nea komt. HAVCR1 kin oars wêze. It kin ek in oar hoopfol laboratoriumresultaat wêze dat yn in kast sit wylst pasjinten fertrage diagnoses bliuwe ûntfangen. De ferantwurdlikheid leit by fabrikanten en sikehûssystemen om it tsjindiel te bewiizen.
A discovery announced this week claims that hepatitis A virus receptor 1, or HAVCR1, shows up in rare brain and spinal cord tumors and eye cancers. The researchers say detecting this protein could replace more invasive diagnostic tests and catch these tumors earlier. That sounds promising on paper. The actual question is whether hospitals will adopt a new testing protocol for diseases that affect perhaps a few thousand people per year across entire continents.
Rare cancers get little research funding precisely because they are rare. Pharmaceutical companies avoid them because the market is small. Hospital systems do not invest in equipment and training for conditions they see once every few years. Even when a better test exists, inertia and cost often mean patients keep getting the old, worse test. A study in a prestigious journal changes nothing by itself.
No one here is saying HAVCR1 testing will not help the people who can access it. The protein genuinely exists in these tumors, and blood tests are cheaper and less invasive than biopsies. But the gap between a research paper and an actual patient getting the right test faster can take a decade or more. Hospitals need diagnostic kit manufacturers to produce reliable HAVCR1 assays. Those companies need a viable market. Insurance systems need to agree to reimburse the test. Doctors need training. Each barrier kills momentum.
The research also does not say how accurate the test is at ruling out other conditions or how many false positives it produces. A biomarker that shows up in tumors is useful only if it does not also show up in benign tissue. The press release side-steps questions about specificity and sensitivity. Those answers matter more than the simple fact that the protein exists.
Rare disease communities often celebrate early research findings and then wait years for commercialization that never comes. HAVCR1 could be different. It could also be another promising lab result that sits on a shelf while patients continue to receive delayed diagnoses. The burden falls on manufacturers and hospital systems to prove otherwise.
Published May 21, 2026 · Frisian News · Ljouwert, Fryslân